Get the Stockscreener App
6.84
0.87%
-0.06
After Hours:
6.90
0.06
+0.88%
Cns Pharmaceuticals Inc stock is traded at $6.84, with a volume of 7,543.
It is down -0.87% in the last 24 hours and down -17.12% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$6.90
Open:
$6.9188
24h Volume:
7,543
Relative Volume:
0.27
Market Cap:
$4.24M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0967
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
+2.09%
1M Performance:
-17.12%
6M Performance:
-48.18%
1Y Performance:
-90.84%
1-Day Range:
$6.745
$7.069
1-Week Range:
$6.2988
$7.069
52-Week Range:
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
6.84 | 4.28M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - The Manila Times
CNS Pharmaceuticals Increases Authorized Shares for Growth - The Globe and Mail
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting - Investing.com India
How strong is CNS Pharmaceuticals Inc. stock revenue growthWeekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
How CNS Pharmaceuticals Inc. stock responds to policy changesQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Can CNS Pharmaceuticals Inc. stock outperform in 2025 bull marketAnalyst Downgrade & Entry and Exit Point Strategies - newser.com
Is CNS Pharmaceuticals Inc. stock gaining market shareJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Is CNS Pharmaceuticals Inc. stock reversal real or fakeJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Trend analysis for CNS Pharmaceuticals Inc. this weekJuly 2025 Momentum & Accurate Technical Buy Alerts - newser.com
Will CNS Pharmaceuticals Inc. stock deliver better than expected guidance2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Full technical analysis of CNS Pharmaceuticals Inc. stockJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Will CNS Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Why CNS Pharmaceuticals Inc. stock remains resilientMarket Growth Summary & Verified Entry Point Detection - newser.com
Will CNS Pharmaceuticals Inc. stock see PE expansion2025 Geopolitical Influence & Safe Investment Capital Preservation Plans - newser.com
CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D - TipRanks
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study - Digital Journal
CNS Pharmaceuticals (CNSP) Advances Lead Product for Brain Cance - GuruFocus
CNSP Forecasts Adequate Funding to Sustain Operations into Late 2026 - GuruFocus
CNS Pharmaceuticals : Reports Third Quarter 2025 Financial Results and Provides Corporate Update - MarketScreener
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update - ACCESS Newswire
CNS Pharmaceuticals (NASDAQ: CNSP) trims Q3 loss, cash funds operations into 2026 - Stock Titan
Can volume confirm reversal in CNS Pharmaceuticals Inc.2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com
Will CNS Pharmaceuticals Inc. stock return to pre crisis levelsInsider Buying & Long Hold Capital Preservation Plans - newser.com
MSN Money - MSN
Will CNS Pharmaceuticals Inc. stock recover after recent drop2025 Earnings Surprises & Technical Pattern Recognition Alerts - newser.com
Is CNS Pharmaceuticals Inc. stock dividend yield sustainableEarnings Trend Report & Weekly Return Optimization Alerts - newser.com
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):